Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for LBL-047 (DNTH212) (BDCA2/TACI Inhibitor) in Dermatomyositis. The expected timing is based on the latest available company guidance and may change.
08/04/26:- DNTH212 selected for dermatomyositis. Healthy volunteer data expected by Year-End 2026.
Verification
Confirm timing and program details against the company announcement or filing.